614749-78-9
614749-78-9 結(jié)構(gòu)式
基本信息
CS-2835
4-[4-(1,3-Benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]bicyclo[2.2.2]octane-1-carboxamide
Bicyclo[2.2.2]octane-1-carboxamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | HY-111482 | SM 16 | 614749-78-9 | 1 mg | 500元 |
| 2025/05/22 | HY-111482 | SM16 SM 16 | 614749-78-9 | 5mg | 1100元 |
| 2025/05/22 | HY-111482 | SM16 SM 16 | 614749-78-9 | 10 mM * 1 mLin DMSO | 1210元 |
常見問題列表
Ki: ALK5 (10 nM), ALK4 (1.5 nM)
SM 16 inhibits TGFβ-induced plasminogen activator inhibitor-luciferase activity (IC 50 =64 nM) and TGFβ- or activin-induced Smad2 phosphorylation at concentrations between 100 and 620 nM. SM 16 is tested against >60 related and unrelated kinases and shows moderate off-target activity only against Raf (IC 50 =1 μM) and p38/SAPKa (IC 50 =0.8 μM). SM 16 exhibits no inhibitory activity against ALK family members ALK1 and ALK6.
SM 16 penetrates tumor cells in vivo , suppressing tumor phosphorylated Smad2/3 levels for at least 3 h following treatment of tumor-bearing mice with a single i.p. bolus of 20 mg/kg SM 16. The growth of established AB12 tumors is significantly inhibited by 5 mg/kg/d SM 16 (P<0.001) delivered via s.c. miniosmotic pumps over 28 days.